Biotech stocks Recursion Pharmaceuticals and CRISPR Therapeutics see price gains

Recursion Pharmaceuticals (NASDAQ:RXRX) saw its share price rise by 9.8% on Wednesday, reaching a high of $3.36. The company maintains a market capitalization of $1.81 billion. Analyst opinions on the stock are mixed; JPMorgan Chase & Co. recently lowered its price target to $10.00 while maintaining an overweight rating, and Morgan Stanley set a $5.30 target. Other ratings include a buy from Needham & Company LLC and a sell rating from Weiss Ratings.

CRISPR Therapeutics (NASDAQ:CRSP) shares increased by 11.2% during mid-day trading on Wednesday, hitting a high of $58.37. The company has a market capitalization of $5.72 billion. Financial institutions have provided varying outlooks, with Citigroup increasing its price target to $88.00 and maintaining a buy rating. Conversely, Goldman Sachs reaffirmed a neutral rating with a $55.00 target, and Weiss Ratings reiterated a sell rating.